rood blauwe elepsis logo Belegger.nl

Delta Lloyd Terug naar discussie overzicht

Delta Lloyd 2016

31.190 Posts
Pagina: «« 1 ... 127 128 129 130 131 ... 1560 »» | Laatste | Omlaag ↓
  1. forum rang 6 trab33 16 maart 2016 13:34
    quote:

    Daniel Fleet schreef op 16 maart 2016 13:22:

    Ben niet helemaal op de hoogte, maar doe ik er goed aan nu nog te kopen?
    volgens mij wel ,er zijn grootaandeelhouders die er aan 15 in zitten en toch met een eventuele emissie meedoen
  2. forum rang 7 A3aan 16 maart 2016 13:50
    Dat gaat voor de instappers van de laatste maanden helemaal goed komen. Voor de aandeelhouder van laten we zeggen 6 maanden terug is het een drama.
  3. forum rang 5 IQ 16 maart 2016 13:56
    quote:

    A3aantje schreef op 16 maart 2016 13:50:

    Dat gaat voor de instappers van de laatste maanden helemaal goed komen. Voor de aandeelhouder van laten we zeggen 6 maanden terug is het een drama.
    Behoudens zij die bijgekocht hebben en hun gemiddelde koers terug gebracht hebben, zou wel zo verstandig geweest zijn, moet je wel centjes voor hebben natuurlijk. Genoeg kansen gehad rond de 4€.
  4. Peter Markus 16 maart 2016 13:56
    Vanmiddag verwacht ik nog wat winstneming van beleggers die op safe spelen.
    Dat is de reden dat ik er op 5.784 even ben uitgestapt.
    Straks pak ik ze weer op.
    Groet PM
  5. forum rang 5 IQ 16 maart 2016 13:59
    Gaat gewoon goed komen, wel met heel veel geduld, maar dividend is best wel goed te noemen, zeker als je het vergelijkt met huidige bankrente, 8/9 euro acht ik niet uitgesloten eind dit jaar, zeker als de claimemissie met succes wordt uitgevoerd zal de rust terugkeren bij DL.
  6. [verwijderd] 16 maart 2016 14:04
    Oke dus als ik het goed begrijp:
    claimemissie gaat door waarmee DL haar solvabiliteit wil versterken -> stijgende trend houdt aan
    claimemissie wordt geweigerd -> terug omlaag naar misschien wel onder de 5 euro?
  7. forum rang 5 IQ 16 maart 2016 14:07
    quote:

    Daniel Fleet schreef op 16 maart 2016 14:04:

    Oke dus als ik het goed begrijp:
    claimemissie gaat door waarmee DL haar solvabiliteit wil versterken -> stijgende trend houdt aan
    claimemissie wordt geweigerd -> terug omlaag naar misschien wel onder de 5 euro?
    Overname bij het niet doorgaan is de enigen optie voor DL, een gedwongen overname kost altijd heel veel geld, koers zal dan echt doorzakken.
  8. [verwijderd] 16 maart 2016 14:09
    quote:

    IQ schreef op 16 maart 2016 14:07:

    [...]
    Overname bij het niet doorgaan is de enigen optie voor DL, een gedwongen overname kost altijd heel veel geld, koers zal dan echt doorzakken.
    Des te meer redenen voor grootaandeelhouders om de claim door te laten gaan, lijkt mij?
  9. forum rang 5 IQ 16 maart 2016 14:15
    quote:

    Daniel Fleet schreef op 16 maart 2016 14:09:

    [...]

    Des te meer redenen voor grootaandeelhouders om de claim door te laten gaan, lijkt mij?
    In de huidige situatie is er geen andere keus, DL top had maatregelen moeten nemen in juni juli vorig jaar, maar achteraf is altijd makkelijker conclusies te trekken, maar regeren is vooruitkijken, dus de top heeft heel erg slecht geregeerd.
  10. [verwijderd] 16 maart 2016 14:19
    quote:

    streber schreef op 16 maart 2016 13:41:

    Wellicht veiliger om de winst van vandaag veilig te stellen en de uitspraak af te wachten.
    Exact 14 dagen geleden kocht ik ze nog voor 6.08
  11. [verwijderd] 16 maart 2016 14:33
    Nice!

    Delta Lloyd N.V. ('Delta Lloyd') and Fubon Financial Holding Co.
    ('Fubon') have agreed to continue their discussions regarding forming an
    enhanced partnership. Delta Lloyd is also pleased with the announcement
    of Fubon of its commitment to exercise all the rights in respect of its
    shareholding (c.7% of Delta Lloyd's share capital) and to vote in favour
    of the proposed rights issue at today's EGM.
    Fubon and Delta Lloyd have signed a heads of agreement detailing
    arrangements which are also intended to form the basis for further
    discussion

    -- Delta Lloyd will support Fubon's intention to acquire further ordinary
    shares and rights of Delta Lloyd in the open market or in any rump
    placement, subject to applicable securities law in connection with the
    rights issue and to assist in any necessary regulatory clearance; and
    -- Delta Lloyd has also agreed to nominate (through its Supervisory Board)
    one individual designated by Fubon for appointment to Delta Lloyd's
    Supervisory Board, subject to applicable approvals and employee
    consultation, if Fubon reaches a 15% ordinary share ownership position
    (on a fully diluted basis).

    In the event that Fubon reaches a 15% ownership position, Fubon and
    Delta Lloyd will negotiate in good faith to enter into a relationship
    agreement(1) . Fubon and Delta Lloyd have agreed to explore
    opportunities for business co-operation for the benefit of both groups,
    for example asset management opportunities, reinsurance agreements and
    knowledge exchange. Any such arrangements will be on an arm's length
    basis.
    Fubon may act as a sub-underwriter of the rights issue in respect of all
    the rights that would be allocated to it in respect of its shareholding.
    Hans van der Noordaa: "We welcome our enhanced partnership with Fubon
    and are looking forward to a long term mutually beneficial relationship.
    We have been in constructive dialogue with Fubon on such a relationship
    for quite some time, and we are confident that the proposed partnership
    will be to the benefit of all stakeholders."
    (1) In terms customary for relationship agreements in the Dutch market
    including customary standstill arrangements (i.e. Fubon not increasing
    its shareholding in Delta Lloyd above 20% without the prior written
    approval of Delta Lloyd) and provisions relating to exchange of
    information and Fubon's nomination right in respect of a seat on Delta
    Lloyd's Supervisory Board.
    Disclaimer
    The information contained herein is not for release, publication or
    distribution, directly or indirectly, in or into any jurisdiction in
    which the distribution or release would be unlawful. This press release
    does not constitute an offer to sell, or a solicitation of offers to
    purchase or subscribe for, securities in the United States or any other
    jurisdiction. The securities to be offered in the proposed rights
    offering have not been, and will not be, registered under the Securities
    Act of 1933 (the "Securities Act"), as amended, and may not be offered,
    exercised or sold in the United States absent registration or pursuant
    to an applicable exemption from or in a transaction not subject to, the
    registration requirements of the Securities Act. There is no intention
    to register any portion of the offering in the United States or to
    conduct a public offering of securities in the United States.
    This press release contains regulated information (gereglementeerde
    informatie) within the meaning of the Dutch Financial Supervision Act
    (Wet op het financieel toezicht) which must be made publicly available
    pursuant to Dutch law.
    Certain statements contained in this press release that are not
    historical facts are "forward-looking statements". Forward-looking
    statements are typically identified by the use of forward looking
    terminology such as "believes", "expects", "may", "will", "could",
    "should", "intends", "estimates", "plans", "assumes", "anticipates",
    "annualised", "goal", "target" or "aim" or the negative thereof or other
    variations thereof or comparable terminology, or by discussions of
    strategy that involve risk and uncertainties. The forward-looking
    statements in this press release are based on management's beliefs and
    projections and on information currently available to them. These
    forward-looking statements are subject to a number of risks and
    uncertainties, many of which are beyond Delta Lloyd's control and all of
    which are based on management's current beliefs and expectations about
    future events.
    Forward-looking statements involve inherent risks and uncertainties and
    speak only as of the date they are made. Delta Lloyd undertakes no duty
    to and will not update any of the forward-looking statements in light of
    new information or future events, except to the extent required by
    applicable law. A number of important factors could cause actual results
    or outcomes to differ materially from those expressed in any
    forward-looking statement as a result of risks and uncertainties facing
    Delta Lloyd and its subsidiaries. Such risks, uncertainties and other
    important factors include, among others: (i) changes in the financial
    markets and general economic conditions, (ii) changes in competition
    from local, national and international companies, new entrants in the
    market and self-insurance and changes to the competitive landscape in
    which Delta Lloyd operates, (iii) the adoption of new, or changes to
    existing, laws and regulations including Solvency II, (iv) catastrophes
    and terrorist-related events, (v) default by third parties owing money,
    securities or other assets on their financial obligations, (vi) equity
    market losses, (vii) long- and/or short-term interest rate volatility,
    (viii) illiquidity of certain investment assets, (ix) flaws in
    underwriting assumptions, pricing and/or claims reserves, (x) the
    termination of or changes to relationships with principal intermediaries
    or partnerships, (xi) the unavailability and unaffordability of
    reinsurance, (xii) flaws in Delta Lloyd's underwriting, operating
    controls or IT systems, or a failure to prevent fraud, (xiii) a
    downgrade (or potential downgrade) of Delta Lloyd's credit ratings, and
    (xiv) the outcome of pending, threatened or future litigation or
    investigations, or other factors referred to in this press release.
    Should one or more of these risks or uncertainties materialise, or
    should any underlying assumptions prove to be incorrect, Delta Lloyd's
    actual financial condition or results of operations could differ
    materially from those described herein as anticipated, believed,
    estimated or expected.
    Please see the Annual Report for the year-ended 31 December 2015 for a
    description of certain important factors, risks and uncertainties that
    may affect Delta Lloyd's businesses.
    Persbericht (ENG): hugin.info/142905/R/1995027/734796.pdf
    This announcement is distributed by NASDAQ OMX Corporate Solutions on
    behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely
    responsible for the content, accuracy and originality of the information
    contained therein.
    Source: Delta Lloyd via Globenewswire
    HUG#1995027

    www.deltalloyd.com

    (END) Dow Jones Newswires

    March 16, 2016 09:31 ET (13:31 GMT)
31.190 Posts
Pagina: «« 1 ... 127 128 129 130 131 ... 1560 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.544
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.589
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.732
Aedifica 3 903
Aegon 3.258 322.688
AFC Ajax 538 7.087
Affimed NV 2 6.292
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.331
Air France - KLM 1.025 35.024
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.700
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.934
AMG 971 133.209
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.663
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.296
Aroundtown SA 1 219
Arrowhead Research 5 9.731
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.089
ASML 1.766 106.514
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392